Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMVT-1402 long-term extension in adults with Graves' disease
jRCT2041260105Not yet recruiting
- Sponsor
- Immunovant, Inc.
- Start
- Jan 2027
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label trial of IMVT-1402 in Graves' disease (3 arms), sponsored by Immunovant, Inc. Primary endpoint: Percentage of Group A participants who remain euthyroid, off antithyroid drugs, and off IMVT-1402 at Week 52. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
IMVT-1402
03
Conditions
Graves' disease
Beyond the preview
Go deeper on jRCT2041260105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041260105.